Categories
Nevin Manimala Statistics

Freshwater aquaculture in the Indian Sundarbans: expansion, challenges, and climate change adaptation

Environ Monit Assess. 2025 Oct 6;197(11):1178. doi: 10.1007/s10661-025-14650-x.

ABSTRACT

Freshwater aquaculture in the Indian Sundarbans has witnessed significant growth over the past four decades, largely driven by declining agricultural viability due to increasing soil salinization, erratic rainfall, and rising demand for fish protein. This study aims to assess the spatial and temporal expansion of freshwater aquaculture from 1985 to 2024 and evaluate its production outcomes and livelihood implications. Employing a mixed-methods approach, the analysis integrates remote sensing data (Landsat and Sentinel-2 imagery), supervised and unsupervised land use classification, and field surveys involving 350 fish-farming households. Results indicate a 96.9% increase in aquaculture area-from 80.54 km2 in 1985 to 860.96 km2 in 2024-with growth concentrated in Pathar Pratima, Gosaba, and Basanti blocks. The majority (82.12%) of ponds are small-scale, yielding an average household production of 87 kg and generating ₹13,918 annually, with a mean productivity of 120 kg/ha/year. Labeo rohita and Labeo catla are the dominant cultured species. Despite expansion, key challenges include seed and feed shortages, salinity intrusion, and inadequate infrastructure. Government interventions such as MGNREGS and the Jal Dharo Jal Bharo scheme have facilitated water management and pond development. The findings underscore the need for strategic ecological planning and policy support to ensure the sustainability and climate resilience of freshwater aquaculture in this vulnerable coastal ecosystem.

PMID:41051654 | DOI:10.1007/s10661-025-14650-x

Categories
Nevin Manimala Statistics

Regionally Specific Resting-State Beta Neural Power Predicts Brain Injury and Symptom Recovery in Adolescents with Concussion: A Longitudinal Study

J Neurotrauma. 2025 Oct 6. doi: 10.1177/08977151251383542. Online ahead of print.

ABSTRACT

Mild traumatic brain injury (mTBI) is common in adolescents. Magnetoencephalography (MEG) studies (primarily reporting on adult males) have demonstrated abnormal resting-state (RS) brain activity in mTBI. The present study sought to identify RS abnormalities in male and female adolescents with mTBI (no previous Diagnostic and Statistical Manual of Mental Disorders – 5th Edition diagnosis) identified from an outpatient specialty care concussion program setting as a basis for evaluating potential clinical utility. Visit 1 MEG RS data were obtained from 46 adolescents with mTBI (mean age: 15.4 years, 25 females) within 4 months of a mTBI (mTBI acute to subacute period) as well as from 34 typically developing (TD) controls (mean age: 14.8 years; 17 females) identified from the local community. Visit 2 RS data (follow-up ∼4.3 months after Visit 1; mTBI subchronic period) were obtained from 36 mTBI (19 females) and 29 TD (14 females) of those participants. Source-space RS neural activity was examined from 4 to 56 Hz. Visit 1 t-tests showed that group differences were largest in the beta range (16-30 Hz; mTBI < TD), with whole-brain linear mixed model (LMM) analyses examining beta-band group differences as a function of Visit. A main effect of Group indicated Visits 1 and 2 beta-band group differences in midline superior frontal gyrus, right temporal pole, and right central sulcus (all mTBI < TD). The group effects were large (Cohen’s d values 0.75 to 1.31). Of clinical significance in the mTBI group, a decrease in mTBI symptoms from Visit 1 to 2 was associated with an increase in beta power in 4 other brain regions. Present findings suggest that RS beta power has potential as a measure and perhaps as a mechanism of clinical recovery in adolescents with mTBI.

PMID:41048046 | DOI:10.1177/08977151251383542

Categories
Nevin Manimala Statistics

Inhibition of butyrylcholinesterase in a population exposed to insecticides during a campaign against Aedes aegypti

Trans R Soc Trop Med Hyg. 2025 Oct 6:traf108. doi: 10.1093/trstmh/traf108. Online ahead of print.

ABSTRACT

BACKGROUND: Chemical control remains a widely used strategy to reduce morbidity from vector-borne diseases such as dengue. However, the potential health risks to exposed populations necessitates ongoing monitoring, particularly due to the toxicity and volume of insecticides employed.

METHODS: This study assessed butyrylcholinesterase activity in residents of a city in southern Mexico during distinct periods of exposure to carbamate and organophosphate insecticides.

RESULTS: A statistically significant inhibition of enzymatic activity was observed during the rainy season, which coincided with an increase in insecticide application.

CONCLUSIONS: These findings highlight the need for public health authorities to implement preventative measures aimed at minimizing poisoning risks associated with vector control activities.

PMID:41048036 | DOI:10.1093/trstmh/traf108

Categories
Nevin Manimala Statistics

Digging Deeper Into Cardiovascular Plasma Proteomics: Opportunities and Limitations of Current Platforms

Circ Genom Precis Med. 2025 Oct 6:e005198. doi: 10.1161/CIRCGEN.125.005198. Online ahead of print.

ABSTRACT

Coronary artery disease remains the leading cause of death worldwide. One of the greatest developments in preventive cardiology has been the identification and treatment of standard modifiable risk factors associated with coronary artery disease. However, despite advances in the management of standard modifiable risk factors, there is an escalating number of patients who continue to present with acute coronary syndromes, a trend that is particularly concerning given the decreasing age-adjusted incidence rates of these conditions. This persistent clinical challenge underscores the urgency to explore alternative approaches for early detection and improved risk stratification. In recent years, the emergence of proteomics technologies has brought forth promising avenues for the discovery of novel biomarkers that hold the potential to revolutionize the timely detection and management of coronary artery disease. Proteomics enables the high throughput and often unbiased analysis of protein abundance, modifications, and interactions within pathways relevant to cardiovascular disease pathogenesis. Of particular importance is the capability to detect low-abundance proteins including those with currently unknown functions. While the functional assessment of these proteins aligns more with mechanistic studies, their role in biomarker discovery is equally important. Such detection may provide new insights into cardiac pathophysiology, including potential new markers for early disease detection and risk assessment. Although the latest proteomics technology and bioinformatic approaches do provide the opportunity for novel discoveries, understanding the limitations of each technology platform is important. This review provides an updated overview of major proteomic platforms and discusses their methodological strengths, constraints, and applications, using recent coronary artery disease studies as illustrative examples. By integrating proteomics data with clinical information, including advanced noninvasive imaging techniques and other omics disciplines, such as genomics and metabolomics, we can deepen our understanding of disease mechanisms and improve risk stratification. Although the discovery of novel biomarkers represents a significant step forward in the field, their true clinical value is contingent upon their rigorous validation in clinical trials and implementation studies. With our current capabilities and emerging advancements, we are well-positioned to advance proteomics-guided precision medicine in cardiovascular care over the coming decade.

PMID:41048024 | DOI:10.1161/CIRCGEN.125.005198

Categories
Nevin Manimala Statistics

Implementation of a next-generation sequencing and PD-L1 immunohistochemistry reflex testing protocol for non-small cell lung cancers improves turnaround time

Am J Clin Pathol. 2025 Oct 6:aqaf107. doi: 10.1093/ajcp/aqaf107. Online ahead of print.

ABSTRACT

OBJECTIVE: Targeted therapy in non-small cell lung cancer (NSCLC) is now often included as first-line treatment in the neoadjuvant and adjuvant settings. Delays in optimizing treatments based on biomarker status can affect outcomes. Therefore, we assessed the turnaround time (TAT) of reflex biomarker testing for all NSCLCs clinical stage 1B and greater.

METHODS: A next-generation sequencing (NGS) and PD-L1 immunohistochemistry reflex protocol for NSCLC clinical stage 1B and greater was implemented. Turnaround time intervals between procedure date, pathology sign-out, date received in the molecular laboratory, and date of NGS sign-out were calculated. Median and IQR of each interval before and after implementation of the reflex protocol were calculated and compared using the Mann-Whitney U test.

RESULTS: In total, 492 lung cancer NGS cases were identified, 351 before and 141 after implementation of the reflex protocol. The prereflex cases, after exclusion of biomarker testing ordered on older blocks and outside consults (n = 165), demonstrated a 22-day median time from procedure to NGS sign-out (range, 11-70 days; IQR, 9; mean, 24 days), compared to a 20-day median time (range, 13-54 days; IQR, 4.5; mean, 21 days) postimplementation (n = 120) (P < .000103).

CONCLUSIONS: Reduction in median TAT from procedure to NGS sign-out was statistically significant after implementation of reflex biomarker testing in NSCLC samples.

PMID:41048009 | DOI:10.1093/ajcp/aqaf107

Categories
Nevin Manimala Statistics

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study

Aliment Pharmacol Ther. 2025 Oct 6. doi: 10.1111/apt.70395. Online ahead of print.

ABSTRACT

BACKGROUND: Faecal microbiota transplantation (FMT) is effective for Clostridioides difficile infection (CDI), but real-world effectiveness data are warranted to refine treatment algorithms. We previously found that FMT effectiveness varied with donors, and the effect of a single capsule FMT administration was lower than expected.

AIMS: To improve FMT outcomes through empirical donor exclusion and application of an optimised capsule FMT dosing regimen.

METHODS: In this multi-site Danish quality improvement study, we included patients with CDI treated with capsule-based FMT from 24 June 2019 to 30 September 2024. The primary outcome was cure of C. difficile-associated diarrhoea (CDAD) 8 weeks after FMT. We assessed this using statistical process control charts monitored separately for the primary FMT centre and the external FMT sites. We used multivariable, mixed-effect logistic regression analysis to evaluate the impact of FMT dosing while adjusting for patient, donor and CDI-related factors.

RESULTS: We included 1176 patients (1707 FMT treatments). At external FMT sites, the cure rate from one FMT treatment changed from 50% (95% confidence interval (CI): 45%-56%) to 59% (55%-63%) following the exclusion of three low-performing donors in November 2022. After implementing a two-dose capsule FMT dosing regimen in February 2024, the cure rate increased to 72% (65%-77%). The impact of the two-dose capsule FMT dosing regimen remained statistically significant after adjustment (odds ratio 1.22; 95% CI 1.16-1.28; p < 0.001).

CONCLUSION: Empirical donor selection and a two-dose capsule FMT regimen improved clinical outcomes in a large-scale system treating patients with CDI.

PMID:41047993 | DOI:10.1111/apt.70395

Categories
Nevin Manimala Statistics

Modelling and Prediction of Permeate Flux in the Ultrafiltration Recovery of Sodium Lignosulfonate from Aqueous Solution

Acta Chim Slov. 2025 Jul 23;72(3):441-449. doi: 10.17344/acsi.2025.9163.

ABSTRACT

Modelling and data fitting for the prediction of permeate flux during ultrafiltration (UF) of a model feed solution of sodium lignosulfonate was carried out following resistance in series, gel polarization and Kedem Katchalsky equations. The experiments were conducted in a laboratory UF unit equipped with PES/HFUF asymmetric membrane under specific operating conditions by altering some parameters including solute concentration, transmembrane pressure (TMP), and cross flow velocity (CFV). The maximum experimental permeate flux was observed at TMP of 3.92 bar and CFV 0.527 ms-1 was 19.6 × 10-6 m3m-2s-1. The theoretical and experimental volumetric flux was plotted, and their extent of resemblance was compared and validated statistically. The study sheds light on the effective upcycling of sodium lignosulfonate from spent liquor via ultrafiltration.

PMID:41047983 | DOI:10.17344/acsi.2025.9163

Categories
Nevin Manimala Statistics

Development of Novel Analgesics Related to TRPV1 Antagonism – In Silico Approach

Acta Chim Slov. 2025 Jul 23;72(3):450-462. doi: 10.17344/acsi.2025.9199.

ABSTRACT

In the context of pharmacological intervention for pain, Transient Receptor Potential Vanilloid, member 1 (TRPV1), as a non-selective cation channel belonging to the transient receptor potential (TRP) family of ion channels, has emerged as a promising target. However, the availability of selective TRPV1 antagonists and their associated pharmacological properties remains limited. This research paper explores various QSAR modeling techniques applied to a range of piperazinyl-aryl compounds acting as TRPV1 antagonists. The descriptors utilized in the creation of conformation-independent QSAR models included local molecular graph invariants and the SMILES notation, along with the incorporation of the Monte Carlo optimization method as a model development technique. Several statistical methods were employed to evaluate the quality, robustness, and predictive capacity of the developed models, yielding positive results. For the best developed QSAR model following statistical parameters were obtained for training set R2 = 0.7155, CCC = 0.8134, IIC = 0.7430, Q2 = 0.6970, RMSE = 0.645, MAE = 0.489 and F = 157; and for test set R2 = 0.9271, CCC = 0.9469, IIC = 0.9635, Q2 = 0.9241, RMSE = 0.367, MAE = 0.329 and F = 328. Additionally, molecular fragments derived from SMILES notation descriptors, which explain observed changes in the evaluated activity, were identified, leading to the design of four new antagonists. The final validation of the QSAR model and the designed antagonists was conducted through molecular docking, which demonstrated strong correlation with the QSAR modeling results.

PMID:41047980 | DOI:10.17344/acsi.2025.9199

Categories
Nevin Manimala Statistics

SPINK4 Expression as a Predictive Biomarker for Radiolabeled Immune Modulator Therapy in Advanced Colorectal Cancer

Cancer Biother Radiopharm. 2025 Oct 6. doi: 10.1177/10849785251379696. Online ahead of print.

ABSTRACT

Colorectal cancer (CRC) remains a significant factor contributing to the morbidity and mortality rates linked with cancer throughout the world, especially in its stages of progression. Increasingly attractive therapeutic options include immune modulation combined with preoperative chemotherapy and radiation therapy (CRT). Recent studies have revealed that the protein serine peptidase inhibitor Kazal type 4 (SPINK4), which is abundantly expressed in gastrointestinal tract tissues, plays a role in immune evasion and treatment resistance in cancers. This meta-analysis aims to assess the relationship between SPINK4 expression levels and the therapeutic effectiveness of radiolabeled immune modulators in patients with advanced CRC who are undergoing preoperative chemotherapy and radiation treatment. The degree of SPINK4 expression and a lower objective response to radiolabeled immune modulators showed a statistically significant link. Conversely, patients with low SPINK4 expression have more favorable treatment responses and ongoing clinical improvement following CRT. High SpINK4 expression can act as a negative prognostic biomarker for radiolabeled immune control in advanced CRC.

PMID:41047949 | DOI:10.1177/10849785251379696

Categories
Nevin Manimala Statistics

Evaluation of the Medicines and Healthcare products Regulatory Agency’s introduction of a risk-proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024

Br J Clin Pharmacol. 2025 Oct 6. doi: 10.1002/bcp.70308. Online ahead of print.

ABSTRACT

AIMS: The Medicines and Healthcare products Regulatory Agency (MHRA) introduced a risk-proportionate approach to assess clinical trial applications for authorisation in August 2023. This study evaluates the impact of this approach on the timelines for reviewing proposals.

METHODS: Data on new clinical trial initial submissions and substantial amendments were extracted from the MHRA’s clinical trials unit database. The primary endpoint was the number of days for the MHRA’s first review of initial applications. The secondary endpoints were the days taken by the sponsor’s replies to grounds for nonacceptance, the MHRA’s days to issue the final decision and the percentage of reviews within statutory timelines. For substantial amendments, the days for the final decision and the percentage of statutory timelines met were the endpoints.

RESULTS: Between September 2023 and August 2024, 4617 applications were received, 615 relating to initial clinical trial submissions, while 4002 were substantial amendments. The first review was completed within the statutory timelines for 99% of submissions, with a median of 28 days (interquartile range [IQR] 27-30); 48.5% of sponsors’ replies to grounds for nonacceptance met the statutory timelines with no statistically significant difference between the commercial and noncommercial sponsors (median 15 days, IQR 9-22). The final decision from the MHRA was within the nonstatutory timelines (median 15 days, IQR 13-27); 99.9% of the substantial amendments were completed within the statutory timelines (median 31 days, IQR 24-34).

CONCLUSION: The MHRA’s risk-proportionate approach enabled the Clinical Trials Unit to consistently meet its timelines, confirming its reliability, consistency and predictability while maintaining its priority to protect patient safety.

PMID:41047928 | DOI:10.1002/bcp.70308